| Name |
Serevent Inhaler 25 mikrograma/dozi, stlačeni inhalat, suspenzija |
| Marketing Authorisation Number |
HR-H-899859080 |
| Active Substance |
salmeterolksinafoat |
| Composition |
jedna inhalacijska doza (ispuštena iz ventila) sadrži 25 mikrograma salmeterola u obliku salmeterolksinafoata |
| Pharmaceutical Form |
stlačeni inhalat, suspenzija |
| Manufacturer |
Glaxo Wellcome Production, Evreux, Francuska |
| Marketing Authorisation Holder |
GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irska |
| Marketing Authorisation Date |
20.08.2021 |
| MA Period of Validity |
unlimited |
| Classification Number |
UP/I-530-09/15-02/404 |
| Registration Number |
381-12-01/70-21-11 |
| Prescription |
Medicinal product subject to medical prescription |
| Type of prescription |
Medicinal product on medical prescription for renewable delivery
|
| Distribution |
Supply through pharmacies (community) |
| Advertising to general public |
not allowed |
| ATC Code |
R03AC12 |
| Marketing status |
Marketed |
| Shortage status |
No shortage |
| SmPC |
download |
| PL |
download |
